使用OKT3联合环孢素和类固醇来逆转急性肾和肝移植排斥反应。
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection.
作者信息
Fung J J, Demetris A J, Porter K A, Iwatsuki S, Gordon R D, Esquivel C O, Jaffe R, Tzakis A, Shaw B W, Starzl T E
出版信息
Nephron. 1987;46 Suppl 1(Suppl 1):19-33. doi: 10.1159/000184431.
Abstract
OKT3 monoclonal antibody therapy was added to preexisting baseline immunosuppressive treatment with ciclosporin and steroids to treat rejection in 52 recipients of cadaveric livers and 10 recipients of cadaveric kidneys. Rejection was controlled in 75% of patients treated, often after high-dose steroid therapy had failed. Rejection recurred during the 17-month follow-up period, after completion of OKT3, in only 25% of the patients who had responded. The safety and effectiveness of this monoclonal therapy, added to ciclosporin and steroids, has been established in this study.
摘要
在52名尸体肝脏移植受者和10名尸体肾脏移植受者中，在已有的环孢素和类固醇基线免疫抑制治疗基础上加用OKT3单克隆抗体疗法来治疗排斥反应。在接受治疗的患者中，75%的患者排斥反应得到控制，这通常是在大剂量类固醇治疗失败之后。在完成OKT3治疗后的17个月随访期内，只有25%有反应的患者排斥反应复发。本研究证实了在环孢素和类固醇基础上加用这种单克隆疗法的安全性和有效性。
相似文献
1
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection.
Nephron. 1987;46 Suppl 1(Suppl 1):19-33. doi: 10.1159/000184431.
2
Monoclonal antibody therapy with ciclosporin and steroids in nonmatched cadaveric renal transplants.
Nephron. 1987;46 Suppl 1(Suppl 1):56-9. doi: 10.1159/000184436.
3
Monoclonal antibody OKT3 therapy in pediatric kidney transplant recipients.
J Pediatr. 1990 May;116(5):S86-91. doi: 10.1016/s0022-3476(05)82708-8.
4
Use of a brief steroid trial before initiating OKT3 therapy for renal allograft rejection.
Am J Kidney Dis. 1988 Feb;11(2):94-8. doi: 10.1016/s0272-6386(88)80187-2.
5
A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.
N Engl J Med. 1985 Aug 8;313(6):337-42. doi: 10.1056/NEJM198508083130601.
6
A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection.
Transplantation. 1987 Jan;43(1):91-5. doi: 10.1097/00007890-198701000-00020.
7
A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection.
Transplant Proc. 1987 Feb;19(1 Pt 3):2431-3.
8
Anti-rejection therapy in renal transplantation: Use of the monoclonal antibody OKT3.
Nephrol Dial Transplant. 1991;6(4):275-9. doi: 10.1093/ndt/6.4.275.
9
A randomized clinical trial of prophylactic OKT3 monoclonal antibody in liver allograft recipients.
Arch Surg. 1990 Jun;125(6):781-4; discussion 785. doi: 10.1001/archsurg.1990.01410180107017.
10
OKT3 monoclonal antibody reversal of renal and hepatic rejection in pediatric patients.
J Pediatr. 1987 Dec;111(6 Pt 2):1046-50. doi: 10.1016/s0022-3476(87)80054-9.
引用本文的文献
1
Origin of lymph node-derived lymphocytes in human hepatic allografts.
Clin Transpl. 1989;3:316-324.
2
WHICH LIVER-DESEASE PATIENTS NEED A TRANSPLANT?: Organ replacement has come into its own as a treatment for end-stage liver disease. A team of experts from two leading transplant centers reviews current indications, survival rates, and methods of evaluating candidates for operation.
Hosp Rec Study. 1988 Jun;10(6):62-79.
3
Transplantation.
JAMA. 1986 Oct 17;256(15):2110-2111. doi: 10.1001/jama.1986.03380150120039.
4
OKT3 and viral disease in pediatric liver transplant recipients.
Clin Transplant. 1991 Aug;5(4):294-300.
5
ORTHOCLONE OKT3 in Treatment of Allografts Rejected Under Cyclosporine-Steroid Therapy.
Transplant Proc. 1986 Aug;18(4):937-941.
6
Gender of donor influences outcome after orthotopic liver transplantation in adults.
Dig Dis Sci. 1993 Aug;38(8):1485-8. doi: 10.1007/BF01308608.
7
Analysis of T lymphocytes infiltrating human hepatic allografts.
Transplant Proc. 1987 Feb;19(1 Pt 3):2470-3.
8
Biliary tract complications in human orthotopic liver transplantation.
Transplantation. 1987 Jan;43(1):47-51. doi: 10.1097/00007890-198701000-00011.
9
The antibody crossmatch in liver transplantation.
Surgery. 1986 Oct;100(4):705-15.
10
The Lewis blood group system in liver transplantation.
Transplant Proc. 1987 Dec;19(6):4591-4.
本文引用的文献
1
Five-Year Survival After Liver Transplantation.
Transplant Proc. 1985 Feb;17(1):259-263.
2
RENAL FAILURE IN PATIENTS WITH CIRRHOSIS OF THE LIVER. I. CLINICAL AND PATHOLOGIC CHARACTERISTICS.
Am J Med. 1965 Aug;39:184-98. doi: 10.1016/0002-9343(65)90041-0.
3
THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE.
Surg Gynecol Obstet. 1963 Oct;117:385-95.
4
Variable convalescence and therapy after cadaveric renal transplantation under cyclosporin A and steroids.
Surg Gynecol Obstet. 1982 Jun;154(6):819-25.
5
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.
Transplantation. 1981 Dec;32(6):535-9. doi: 10.1097/00007890-198112000-00018.
6
Evaluation in primate renal allograft recipients of monoclonal antibody to human T-cell subclasses.
Transplant Proc. 1981 Mar;13(1 Pt 1):499-503.
7
Successful liver transplantation from crossmatch-positive donors.
Transplant Proc. 1981 Mar;13(1 Pt 1):286-8.
8
The use of cyclosporin A and prednisone in cadaver kidney transplantation.
Surg Gynecol Obstet. 1980 Jul;151(1):17-26.
9
Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex.
Cell. 1982 Oct;30(3):735-43. doi: 10.1016/0092-8674(82)90278-1.
10
OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.
J Immunol. 1980 Jun;124(6):2708-13.
Zotero 插件